<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534883</url>
  </required_header>
  <id_info>
    <org_study_id>25065</org_study_id>
    <nct_id>NCT02534883</nct_id>
  </id_info>
  <brief_title>Cervical Ripening in Postmenopausal Women</brief_title>
  <official_title>Cervical Ripening in Postmenopausal Women: A Randomized, Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Misoprostol (Cytotec) 200ug vaginally will be given to patients 12 hours and 2 hours
      pre-operatively (before surgery) for a total of 400ug to ripen, soften or relax the cervix
      for dilation (opening). This is to assist with the insertion of a hysteroscope (the surgical
      instrument) into the uterus for all operative hysteroscopic procedures requiring dilation
      above 5 mm.

      Time required for cervical dilatation will be recorded. Start time will be when the smallest
      dilator is placed into the endocervical canal, and stop time recorded when the desired
      cervical dilation is achieved with the largest dilator. Depending on the procedure, desired
      dilation may range between 5-10mm. Time will serve as a surrogate for operative ease of
      dilatation.

      The investigators will compare the two groups in terms of medication, resistance, dilation
      time and size, side effects and surgical complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, double blinded, placebo controlled trial.

      Patients will be assigned by chance to receive 200ug of misoprostol or placebo (empty gelatin
      capsule) vaginally twice (for a total of 400ug). There is no standard of care, but to receive
      misoprostol or not are both accepted practices and that Standard of Care is for the
      clinicians to use clinical judgment .

      Patients will be randomized to one of the following treatment regimens:

      Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12
      hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol). St.
      Mary's pharmacy will prepare capsules with each containing 200ug of misoprostol.

      Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior
      vaginal fornix 12 hours and 2 hours before their scheduled surgery.

      The two groups, will be compared in terms of side effects, resistance, dilation time, size
      and surgical complication.

      Randomization will occur using a computer program called Research Randomizer,
      http://www.randomizer.org/form.htm. A set of 100 non-unique numbers will be randomized. Once
      the randomization list is generated, envelopes will be made. Based on the randomizer results
      a folder slip of paper with the treatment (misoprostol or placebo) written on it will be
      placed in sequential numbered envelopes. The number on the envelope will be the patients code
      number. An unblinded member of the research team will open the randomized envelope, and log
      into a master drug log the randomization.

      The medication and/or placebo will be place in numbered sequentially bottles with a master
      drug log containing which is misoprostol and which is placebo. Each bottle will have child
      proof lids for dispensing and will be labeled misoprostol 200ug/each/placebo), physician name
      (Ward) and contact number, and &quot;For investigational use only&quot; will also be noted.

      The unblinded staff will notify the research member consenting the patient and inform them of
      what number bottle to give to the patient, in the office before surgery
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    not able to meet enrollment
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy (Cervical Ripening)</measure>
    <time_frame>At time of surgery/cervical dilation</time_frame>
    <description>To evaluate the efficacy of two doses of 200ug of misoprostol (for a total of 400ug), administered vaginally, on cervical ripening before diagnostic and operative hysteroscopic procedures in postmenopausal women (amenorrhea greater than 1 year). Efficacy is represented by time to dilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Recorded Side Effects.</measure>
    <time_frame>At time of surgery/cervical dilation</time_frame>
    <description>Secondary aim: to evaluate if cervical ripening with misoprostol reduces side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilation Time in Minutes</measure>
    <time_frame>At time of procedure.</time_frame>
    <description>Time from beginning of cervical dilation to completion of cervical dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Dilator Size</measure>
    <time_frame>At time of procedure.</time_frame>
    <description>The largest cervical dilator that could be passed through the internal cervical os.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Complications</measure>
    <time_frame>At time of procedure.</time_frame>
    <description>Count of complications at time of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance Score</measure>
    <time_frame>At time of procedure.</time_frame>
    <description>Ease of Dilation Per Surgeon on a numeric scale of 1(easier than normal) to 5 (more difficult than normal) with 3 being &quot;normal.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Stenosis of Cervix</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>To be place vaginally</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>To be placed vaginally</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>non active drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45-80yrs of age

          -  Postmenopausal (amenorrhea for greater than 1 year)

          -  May or may not be using hormone replacement therapy

          -  Scheduled or to be scheduled for hysteroscopy/resectoscopy procedures

        Exclusion Criteria:

          -  Pregnant

          -  Known Cancer

          -  Known hypersensitivity to prostaglandins.

          -  Those who are breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Ward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Health Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <results_first_submitted>February 1, 2018</results_first_submitted>
  <results_first_submitted_qc>June 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Donald Gregory Ward, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol Group</title>
          <description>Group 1 will receive 200 ug of misoprostol to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery (a total of 400 ug misoprostol).
Misoprostol: To be placed vaginally</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Group 1 will receive placebo (empty gelatin capsule) to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery.
Placebo: To be placed vaginally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Termination</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Data not compiled because of early termination</population>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol Group</title>
          <description>Group 1 will receive 200 ug of misoprostol to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery (a total of 400 ug misoprostol).
Misoprostol: To be placed vaginally
Baseline characteristics not compiled because of early termination.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Group 1 will receive placebo (empty gelatin capsule) to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery.
Placebo: To be placed vaginally
Baseline characteristics not compiled because of early termination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>11 enrolled. One participant withdrew because her surgery was cancelled and not rescheduled.
Data sheet completed at time of surgery and thus only available for 10 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>11 enrolled. One participant withdrew because her surgery was cancelled and not rescheduled.
Data sheet completed at time of surgery and thus only available for 10 participants.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="5.2"/>
                    <measurement group_id="B2" value="58.7" spread="6.1"/>
                    <measurement group_id="B3" value="61.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy (Cervical Ripening)</title>
        <description>To evaluate the efficacy of two doses of 200ug of misoprostol (for a total of 400ug), administered vaginally, on cervical ripening before diagnostic and operative hysteroscopic procedures in postmenopausal women (amenorrhea greater than 1 year). Efficacy is represented by time to dilation.</description>
        <time_frame>At time of surgery/cervical dilation</time_frame>
        <population>Outcome measures presented below.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (Cervical Ripening)</title>
          <description>To evaluate the efficacy of two doses of 200ug of misoprostol (for a total of 400ug), administered vaginally, on cervical ripening before diagnostic and operative hysteroscopic procedures in postmenopausal women (amenorrhea greater than 1 year). Efficacy is represented by time to dilation.</description>
          <population>Outcome measures presented below.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.1"/>
                    <measurement group_id="O2" value="1.4" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recorded Side Effects.</title>
        <description>Secondary aim: to evaluate if cervical ripening with misoprostol reduces side effects</description>
        <time_frame>At time of surgery/cervical dilation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recorded Side Effects.</title>
          <description>Secondary aim: to evaluate if cervical ripening with misoprostol reduces side effects</description>
          <units>number of side effects out of seven</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>side effects</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side effects</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.1"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dilation Time in Minutes</title>
        <description>Time from beginning of cervical dilation to completion of cervical dilation.</description>
        <time_frame>At time of procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Dilation Time in Minutes</title>
          <description>Time from beginning of cervical dilation to completion of cervical dilation.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.1"/>
                    <measurement group_id="O2" value="1.4" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Dilator Size</title>
        <description>The largest cervical dilator that could be passed through the internal cervical os.</description>
        <time_frame>At time of procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Dilator Size</title>
          <description>The largest cervical dilator that could be passed through the internal cervical os.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="4.8"/>
                    <measurement group_id="O2" value="6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Complications</title>
        <description>Count of complications at time of surgery.</description>
        <time_frame>At time of procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Complications</title>
          <description>Count of complications at time of surgery.</description>
          <units>complications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resistance Score</title>
        <description>Ease of Dilation Per Surgeon on a numeric scale of 1(easier than normal) to 5 (more difficult than normal) with 3 being &quot;normal.&quot;</description>
        <time_frame>At time of procedure.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
Misoprostol: To be place vaginally</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
Placebo: To be placed vaginally</description>
          </group>
        </group_list>
        <measure>
          <title>Resistance Score</title>
          <description>Ease of Dilation Per Surgeon on a numeric scale of 1(easier than normal) to 5 (more difficult than normal) with 3 being &quot;normal.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2"/>
                    <measurement group_id="O2" value="2.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol Group</title>
          <description>Group 1 will receive 200 ug of misoprostol to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery (a total of 400 ug misoprostol).
Misoprostol: To be placed vaginally</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Group 1 will receive placebo (empty gelatin capsule) to be placed into the posterior vaginal fornix 12 hours and 2 hours before the scheduled surgery.
Placebo: To be placed vaginally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Donald Gregory Ward, MD</name_or_title>
      <organization>St. Louis University</organization>
      <phone>314-781-1505 ext 1</phone>
      <email>dgreg.ward@health.slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

